Cargando…

Mechanistic insights into the rational design of masked antibodies

Although monoclonal antibodies have greatly improved cancer therapy, they can trigger side effects due to on-target, off-tumor toxicity. Over the past decade, strategies have emerged to successfully mask the antigen-binding site of antibodies, such that they are only activated at the relevant site,...

Descripción completa

Detalles Bibliográficos
Autores principales: Orozco, Carolina T., Bersellini, Manuela, Irving, Lorraine M., Howard, Wesley W., Hargreaves, David, Devine, Paul W. A., Siouve, Elise, Browne, Gareth J., Bond, Nicholas J., Phillips, Jonathan J., Ravn, Peter, Jackson, Sophie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272835/
https://www.ncbi.nlm.nih.gov/pubmed/35799328
http://dx.doi.org/10.1080/19420862.2022.2095701
_version_ 1784744953845383168
author Orozco, Carolina T.
Bersellini, Manuela
Irving, Lorraine M.
Howard, Wesley W.
Hargreaves, David
Devine, Paul W. A.
Siouve, Elise
Browne, Gareth J.
Bond, Nicholas J.
Phillips, Jonathan J.
Ravn, Peter
Jackson, Sophie E.
author_facet Orozco, Carolina T.
Bersellini, Manuela
Irving, Lorraine M.
Howard, Wesley W.
Hargreaves, David
Devine, Paul W. A.
Siouve, Elise
Browne, Gareth J.
Bond, Nicholas J.
Phillips, Jonathan J.
Ravn, Peter
Jackson, Sophie E.
author_sort Orozco, Carolina T.
collection PubMed
description Although monoclonal antibodies have greatly improved cancer therapy, they can trigger side effects due to on-target, off-tumor toxicity. Over the past decade, strategies have emerged to successfully mask the antigen-binding site of antibodies, such that they are only activated at the relevant site, for example, after proteolytic cleavage. However, the methods for designing an ideal affinity-based mask and what parameters are important are not yet well understood. Here, we undertook mechanistic studies using three masks with different properties and identified four critical factors: binding site and affinity, as well as association and dissociation rate constants, which also played an important role. HDX-MS was used to identify the location of binding sites on the antibody, which were subsequently validated by obtaining a high-resolution crystal structure for one of the mask-antibody complexes. These findings will inform future designs of optimal affinity-based masks for antibodies and other therapeutic proteins.
format Online
Article
Text
id pubmed-9272835
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-92728352022-07-12 Mechanistic insights into the rational design of masked antibodies Orozco, Carolina T. Bersellini, Manuela Irving, Lorraine M. Howard, Wesley W. Hargreaves, David Devine, Paul W. A. Siouve, Elise Browne, Gareth J. Bond, Nicholas J. Phillips, Jonathan J. Ravn, Peter Jackson, Sophie E. MAbs Report Although monoclonal antibodies have greatly improved cancer therapy, they can trigger side effects due to on-target, off-tumor toxicity. Over the past decade, strategies have emerged to successfully mask the antigen-binding site of antibodies, such that they are only activated at the relevant site, for example, after proteolytic cleavage. However, the methods for designing an ideal affinity-based mask and what parameters are important are not yet well understood. Here, we undertook mechanistic studies using three masks with different properties and identified four critical factors: binding site and affinity, as well as association and dissociation rate constants, which also played an important role. HDX-MS was used to identify the location of binding sites on the antibody, which were subsequently validated by obtaining a high-resolution crystal structure for one of the mask-antibody complexes. These findings will inform future designs of optimal affinity-based masks for antibodies and other therapeutic proteins. Taylor & Francis 2022-07-07 /pmc/articles/PMC9272835/ /pubmed/35799328 http://dx.doi.org/10.1080/19420862.2022.2095701 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Report
Orozco, Carolina T.
Bersellini, Manuela
Irving, Lorraine M.
Howard, Wesley W.
Hargreaves, David
Devine, Paul W. A.
Siouve, Elise
Browne, Gareth J.
Bond, Nicholas J.
Phillips, Jonathan J.
Ravn, Peter
Jackson, Sophie E.
Mechanistic insights into the rational design of masked antibodies
title Mechanistic insights into the rational design of masked antibodies
title_full Mechanistic insights into the rational design of masked antibodies
title_fullStr Mechanistic insights into the rational design of masked antibodies
title_full_unstemmed Mechanistic insights into the rational design of masked antibodies
title_short Mechanistic insights into the rational design of masked antibodies
title_sort mechanistic insights into the rational design of masked antibodies
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272835/
https://www.ncbi.nlm.nih.gov/pubmed/35799328
http://dx.doi.org/10.1080/19420862.2022.2095701
work_keys_str_mv AT orozcocarolinat mechanisticinsightsintotherationaldesignofmaskedantibodies
AT bersellinimanuela mechanisticinsightsintotherationaldesignofmaskedantibodies
AT irvinglorrainem mechanisticinsightsintotherationaldesignofmaskedantibodies
AT howardwesleyw mechanisticinsightsintotherationaldesignofmaskedantibodies
AT hargreavesdavid mechanisticinsightsintotherationaldesignofmaskedantibodies
AT devinepaulwa mechanisticinsightsintotherationaldesignofmaskedantibodies
AT siouveelise mechanisticinsightsintotherationaldesignofmaskedantibodies
AT brownegarethj mechanisticinsightsintotherationaldesignofmaskedantibodies
AT bondnicholasj mechanisticinsightsintotherationaldesignofmaskedantibodies
AT phillipsjonathanj mechanisticinsightsintotherationaldesignofmaskedantibodies
AT ravnpeter mechanisticinsightsintotherationaldesignofmaskedantibodies
AT jacksonsophiee mechanisticinsightsintotherationaldesignofmaskedantibodies